HFE Antikörper (AA 262-348)

Produktnummer ABIN1714561

Produktdetails anti-HFE Antikörper

Target: HFE (Hemochromatosis (HFE))

Bindungsspezifität: AA 262-348

Reaktivität: Human

Wirt: Kaninchen

Klonalität: Polyklonal

Konjugat: Dieser HFE Antikörper ist unkonjugiert

Applikation: Western Blotting (WB), ELISA, Flow Cytometry (FACS), Immunofluorescence (Cultured Cells) (IF (cc)), Immunofluorescence (Paraffin-embedded Sections) (IF (p)), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)), Immunocytochemistry (ICC), Immunohistochemistry (Frozen Sections) (IHC (fro))

Kreuzreaktivität: Human

Homologie: Mouse,Rat,Dog,Cow,Sheep,Horse

Aufreinigung: Purified by Protein A.

Immunogen: KLH conjugated synthetic peptide derived from human HFE/Hemochromatosis

Isotyp: IgG

Anwendungsinformationen

Applikationshinweise: WB 1:300-5000
ELISA 1:500-1000
FCM 1:20-100
IHC-P 1:200-400
IHC-F 1:100-500
IF(IHC-P) 1:50-200
IF(IHC-F) 1:50-200
IF(ICC) 1:50-200
ICC 1:100-500

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Konzentration: 1 μg/μL

Buffer: 0.01M TBS( pH 7.4) with 1 % BSA, 0.02 % Proclin300 and 50 % Glycerol.

Konservierungsmittel: ProClin

Vorsichtsmaßnahmen: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.

Lagerung: 4 °C,-20 °C

Informationen zur Lagerung: Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles.

Haltbarkeit: 12 months

Referenzen für anti-HFE Antikörper (ABIN1714561)

Rychtarcikova, Lettlova, Tomkova, Korenkova, Langerova, Simonova, Zjablovskaja, Alberich-Jorda, Neuzil, Truksa: "Tumor-initiating cells of breast and prostate origin show alterations in the expression of genes related to iron metabolism." in: Oncotarget, Vol. 8, Issue 4, pp. 6376-6398, (2016) (PubMed).

Details zu HFE

Target: HFE (Hemochromatosis (HFE))

Andere Bezeichnung: HFE/Hemochromatosis (HFE Produkte)

Synonyme: HFE1 antikoerper, HH antikoerper, HLA-H antikoerper, MVCD7 antikoerper, TFQTL2 antikoerper, MR2 antikoerper, hemochromatosis antikoerper, HFE antikoerper, Hfe antikoerper

Hintergrund:

Synonyms: dJ221C16.10.1, Hemochromatosis, Hemochromatosis protein, Hereditary hemochromatosis protein, Hereditary hemochromatosis protein HLA H, HFE 1, HFE, HFE_HUMAN, HFE1, HH, High Fe, HLA H, HLA-H, HLAH, MGC:150812, MGC10379, MGC103790, MHC class I like protein HFE, MVCD7, TFQTL2.

Background: The features of hemochromatosis include cirrhosis of the liver, diabetes, hypermelanotic pigmentation of the skin, and heart failure. Since hemochromatosis is a relatively easily treated disorder if diagnosed, this is a form of preventable cancer. The HFE protein, which is defective in hereditary hemo-chromatosis, normally is expressed in crypt enterocytes of the duodenum where it has a unique, predominantly intracellular localization. In placenta, the HFE protein co-localizes with and forms a stable association with the transferrin receptor (TfR), providing a link between the HFE protein and iron transport. Immunocytochemistry shows that the HFE protein and TfR both are expressed in the crypt enterocytes. Western blots show that, as is the case in human placenta, the HFE protein in crypt enterocytes is physically associated with the TfR and with _2-microglobulin. It is proposed that HFE has two mutually exclusive activities in cells: inhibition of uptake or inhibition of release of iron and that the balance between serum transferrin saturation and serum transferrin-receptor concentrations determines which of these functions predominates. The gene which encodes HFE maps to human chromosome 6p21.3.

Gen-ID: 3077

Pathways: Transition Metal Ion Homeostasis, Regulation of Leukocyte Mediated Immunity, Positive Regulation of Immune Effector Process